Pagina inicial
Continue Watching
Últimos vídeos
Últimos vídeos
Brightcove Home Latest Listing
Oncology
Oncology
Brightcove Cards Listing
Hematology
Hematology
Brightcove Cards Listing
Popular em MedEnrich
Popular em MedEnrich
Popular in Sem nome
Câncer de próstata6m 59s
Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
nmcrpc
metastasis free survival
spartan
prosper & aramis clinical trial
1
Managing Nonmetastatic Castration-Resistant...
Myelodysplastic Syndromes23m 43s
Desenvolvimento e Atualizações na Biologia das Mielodisplasias
Desenvolvimento e Atualizações na Biologia das Mielodisplasias (MDS)
síndromes mielodisplásicas
mds
avanços na biologia
terapias inovadoras
epidemiologia da mds
1
Desenvolvimento e Atualizações na Biologia das...
Oncospecials15m 30s
A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais
ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.
oncologia
ccr
câncer renal
tki
sunitinibe
1
A Relevância dos Agentes TKI na era das...
Transplant15m 53s
Profilaxia de CMV em receptores de transplantes
Conheça as estratégias de profilaxia de CMV no pós-transplante de órgãos sólidos, melhor forma de manejo e monitorização de viremia.
cmv
hospitalar
valganciclovir
antiviral
manejo de viremia
transplante
1
Profilaxia de CMV em receptores de transplantes
Mieloma múltiplo7m 42s
MRD Assesment in Multiple Myeloma -Ready for Prime Time
Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
minimum residual disease (mrd)
mrd negativity
multiple myeloma
1
MRD Assesment in Multiple Myeloma -Ready for Prime...
Myelodysplastic Syndromes14m 13s
ASH 2022 Update on Myelodysplastic Syndromes
ASH 2022 - Update on Myelodysplastic Syndromes
low risk mds
venetoclax
viale -a
eln classification
low dose lenalidomide
tags: azacitidine
1
ASH 2022 Update on Myelodysplastic Syndromes
Mieloma múltiplo9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.
pomalidomide-dexamethasone
rrmm management
progression-free survival
combination therapies
1
Integrating Pomalidomide Based Regimens in Multiple...
Acute Myeloid Leukaemia12m 22s
EHA 2022 Updates : AML
EHA Updates AML : QuANTUM phase 3 study showed significant overall survival in adults having FLT3-ITD+ acute myeloid leukaemia with addition of quizartinib to standard induction and consolidation therapy alone.
aml
decitabine
g-csf
hypomethylating agents
1
EHA 2022 Updates : AML
Myelodysplastic Syndromes5m 42s
Integrating Molecular Prognositic Systems in Management of MDS
Integrating molecular prognostic systems into MDS clinical practice enhances risk stratification by combining genetic data with traditional scoring systems.
molecular prognostic systems
ipss-m
prediction of disease progression
1
Integrating Molecular Prognositic Systems in...
nasopharyngeal carcinoma44m 35s
Comprehensive Overview of Nasopharyngeal Carcinoma
Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.
nasopharyngeal carcinoma
immunotherapy
1